Day: March 25, 2024

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

Written by Customer Service on March 25, 2024. Posted in Mergers And Acquisitions.

– Landos’ lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) — AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair. “With this acquisition, we aim to advance the clinical development of NX-13, a differentiated, first-in-class,...

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Written by Customer Service on March 25, 2024. Posted in Earnings Releases And Operating Results.

Key Highlights:Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024. Inflammasome ASC Inhibitor IC 100 preclinical program nearing completion, with planned Investigational New Drug (IND) submission Q4-2024, and Phase 1 clinical trial initiation shortly thereafter. Inflammasome ASC Inhibitor IC 100 preclinical research funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) nearing completion, with potential for a second MJFF grant for further research. Scientific collaboration to assess Inflammasome ASC Inhibitor IC 100 as a potential treatment for atherosclerosis expected to conclude H1-2024. Scientific collaboration to assess Inflammasome ASC Inhibitor IC 100 as a potential treatment for obesity and metabolic syndrome expected to begin Q2-2024.WESTON,...

Brera Scouting Professional Sports Club Acquisitions Including Premium League Targets

Written by Customer Service on March 25, 2024. Posted in Mergers And Acquisitions.

Global Club Owners Eager to Explore Benefits of Nasdaq ListingBREA with John TextorPierre Galoppi (left), Executive Chairman Dan McClory (center), and John Textor (right) the majority owner and chairman of Eagle Football Holdings Limited, the leading shareholder of professional football clubs Botafogo (Brazil), Crystal Palace (England), Olympique Lyonnais (France), Olympique Lyonnais Féminin (France) and RWD Molenbeek (Belgium).DUBLIN, Ireland and MILAN, Italy, March 25, 2024 (GLOBE NEWSWIRE) — Brera Holdings PLC (“Brera Holdings,” “Brera” or the “Company”) (Nasdaq: BREA) provides an update concerning its potential next professional sports club acquisition.Brera’s management team, in consultation with its newly assembled all-star advisory board, has been leveraging their sports and financial industry relationships to...

Bitcoin Depot Reports Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on March 25, 2024. Posted in Earnings Releases And Operating Results.

FY 2023 Record Revenue of $689 Million, Up 7% Year-over-Year FY 2023 Net Income of $1.6 Million, Down 54% Year-over-Year FY 2023 Record Adjusted EBITDA (non-GAAP) of $56 Million, Up 37% Year-over-Year Strengthens Footprint and Continues Business Momentum in the First Quarter of 2024 Provides First Quarter 2024 Guidance for Revenue and Adjusted EBITDA ATLANTA, March 25, 2024 (GLOBE NEWSWIRE) — Bitcoin Depot Inc. (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM operator and leading fintech company, today reported financial results for the fourth quarter and full year ended December 31, 2023. Bitcoin Depot will host a conference call and webcast at 11:00 a.m. ET today. An earnings presentation and link to the webcast will be made available at ir.bitcoindepot.com. “Bitcoin Depot had its strongest year ever in 2023 as we...

Regeneron Provides Update on Biologics License Application for Odronextamab

Written by Customer Service on March 25, 2024. Posted in Public Companies.

TARRYTOWN, N.Y., March 25, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued Complete Response Letters (CRLs) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R) follicular lymphoma (FL) and in R/R diffuse large B-cell lymphoma (DLBCL), each after two or more lines of systemic therapy. The only approvability issue is related to the enrollment status of the confirmatory trials. The CRLs – one for R/R FL and one for R/R DLBCL – did not identify any approvability issues with the odronextamab clinical efficacy or safety, trial design, labeling or manufacturing. Regeneron has been actively enrolling patients in multiple Phase 3 trials for odronextamab as part of the OLYMPIA program – one of the largest...

Aligning Missions, Getting Hired Now Powered by CareerCircle

Written by Customer Service on March 25, 2024. Posted in Mergers And Acquisitions.

Newly Combined Entity Will Further Elevate CareerCircle’s Mission of Connecting Employers with Underrepresented Talent BALTIMORE, March 25, 2024 (GLOBE NEWSWIRE) — Workforce solutions company CareerCircle LLC, an Allegis Group brand, announced today that it has completed the transition of the Getting Hired platform. With this realignment, both companies will operate under the CareerCircle identity, share a leadership team and expand their service offerings. Through the strategic move, Getting Hired Inc., now known as Getting Hired, Powered by CareerCircle, will provide customers with enhanced access to a diverse pool of underrepresented talent, including individuals with disabilities, professionals with disabilities, women, veterans, BIPOC, LGBTQIA+ and more. The combined entity will continue its unwavering support for these communities....

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Written by Customer Service on March 25, 2024. Posted in Public Companies.

Boston (March 25, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that the Company has been granted a formal extension until April 24, 2024 to regain compliance under Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) and 5550(b)(1) (the “Equity Rule”) or any of the alternative requirements in Listing Rule 5550(b). The granting of the extension follows a proactive effort by the Company to address compliance deficiencies and the presentation of a strategic plan to the Nasdaq Hearings Panel on February 1, 2024. The plan contained both immediate and sustained measures aimed at ensuring compliance with both the Bid Price Rule and the Equity Rule. To ensure compliance with the rules of The Nasdaq...

Bombardier’s Global 7500 Jet Sets More Than 30 Speed Records, as Precedent-Setting Program Operates Flawlessly Around the World

Written by Customer Service on March 25, 2024. Posted in Public Companies.

Record-setting flights include Farnborough to Muharraq and Phoenix to Paris which took place on Feb 28 and March 6 Records set as Global 7500 aircraft are actively flying worldwide on customer and demonstrations missions, showcasing this immaculate jet to the public The Global 7500 business jet fleet has surpassed more than 100,000 flying hours and has celebrated more than 165 deliveries With an impressive top speed of Mach 0.925 and a range of 7,700 nautical miles (14,260 km), the Global 7500 business aircraft continues to push the boundaries of business travelMONTRÉAL, March 25, 2024 (GLOBE NEWSWIRE) — Bombardier today celebrated more impressive speed records on the Global 7500 aircraft, bringing the total to more than 30 and counting. The most recent records, including travelling from Farnborough to Muharraq and Phoenix...

SIGA Names Larry Miller General Counsel

Written by Customer Service on March 25, 2024. Posted in Public Companies.

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today. “With over twenty years of experience in the biopharmaceutical industry, Larry brings a proven track record of growing commercial businesses, successful mergers and acquisitions, and strong corporate governance, which are critical to driving SIGA’s continued success and growth strategies forward,” said Diem Nguyen, Chief Executive Officer. “Larry will be instrumental in helping us expand our reach on a global scale and maximize the benefits we bring to patients, customers, and shareholders.” Previously, Mr. Miller served as general counsel and secretary at Phathom Pharmaceuticals,...

Intermap Announces $1 Million Program in Malaysia and Business Updates

Written by Customer Service on March 25, 2024. Posted in Public Companies.

Continuing long-term work with the Malaysian government First payment received and deployment begun for the Indonesian mapping program 2024 year-to-date insurance awards reach $1 million, on track for record year DENVER, March 25, 2024 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial products and intelligence solutions, today announced a $1 million program in Malaysia, an update on its Indonesian mapping program and strong growth in its global insurance business. Enhancing Water Resources Management in Malaysia Intermap won a $1 million contract in Malaysia to enhance water resources management. This award exemplifies how Intermap’s geospatial technology, which incorporates advanced AI/ML-driven automation, is used to commercialize evolving solutions...

Day: March 25, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice